Head and neck cancers survival in Europe, Taiwan, and Japan: results from RARECAREnet Asia based on a privacy-preserving federated infrastructure
Laura Botta(Fondazione IRCCS Istituto Nazionale dei Tumori), Gemma Gatta(Fondazione IRCCS Istituto Nazionale dei Tumori), Matteo Cellamare(Netherlands Comprehensive Cancer Organisation), Chun‐Ju Chiang(National Taiwan University), Carlo Resteghini(Humanitas University), Anna J. van Gestel(Netherlands Comprehensive Cancer Organisation), Wen‐Chung Lee(National Taiwan University), Jéssica Rodrigues(IPO Porto), Lisa Licitra(University of Milan), Annalisa Trama(Fondazione IRCCS Istituto Nazionale dei Tumori), Jordi Rubió‐Casadevall(Catalan Institute for Water Research), Gijs Geleijnse(Netherlands Comprehensive Cancer Organisation), Marcela Guevara(Navarre Institute of Health Research), Rafael Marcos‐Gragera(Generalitat de Catalunya), Stefano Cavalieri(University of Milan), Hadrien Charvat(Juntendo University), Frank Martin(Phospholipid Research Center), S. Bonfarnuzzo(Fondazione IRCCS Istituto Nazionale dei Tumori), Stephanie G. Craig(Queen's University Belfast), Tomohiro Matsuda
Cited by 7
Related Papers
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
|New England Journal of Medicine|2016|5.1k
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
|The Lancet|2018|1.7k
Nivolumab vs investigator’s choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression
|Oral Oncology|2018|802
Global burden of cancer in 2020 attributable to alcohol consumption: a population-based study
|The Lancet Oncology|2021|684
Burden and centralised treatment in Europe of rare tumours: results of RARECAREnet—a population-based study
|The Lancet Oncology|2017|498